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Abstract 
Background: The purpose of this study was to explore gene copy number (GCN) variation of EGFR, HER2, c‑MYC, and 
MET in patients with primary colorectal cancer (CRC).
Methods: Dual‑colour silver‑enhanced in situ hybridization was performed in tissue samples of 334 primary CRC 
patients. The amplification status (GCN ratio ≥2) and GCN gain (average GCN ≥4) data for the EGFR, HER2, c‑MYC and 
MET genes were obtained. GCN variation was also assessed by the criterion of the 2013 ASCO/CAP guidelines for 
HER2 testing.
Results: Amplification of EGFR, HER2, c‑MYC and MET was detected in 8 (2.4%), 20 (6.0%), 29 (8.7%), and 14 (4.2%) 
patients, respectively. Of 66 patients with at least one amplified gene, five exhibited co‑amplification of genes studied 
(HER2‑MET co‑amplification: two patients; HER2‑c‑MYC co‑amplification: two patients; EGFR‑c‑MYC co‑amplification: 
one patient). There were 109 patients with GCN gains of one or more genes (EGFR: 11/334, HER2: 29/334, c‑MYC; 
60/334, MET: 48/334) and 32.1% (35/109) had multiple GCN gains. When each GCN was assessed by the criterion of 
the ASCO/CAP 2013 guideline for HER2 testing, 116 people showed positive or equivocal results for one or more 
genes. The cumulative amplification status had no association with patients’ outcome. However, the cumulative 
results of the GCN gain and GCN status determined according to the ASCO/CAP guideline had a significant prognos‑
tic correlation in the univariate analysis (P values of 0.006 and 0.022, respectively). In the multivariate analysis, GCN 
gain and GCN status were independent prognostic factors (P values of 0.010 and 0.017, respectively).
Conclusions: In this study, we evaluated GCN variation of four genes in a large sample of Korean CRC patients. The 
amplification status was not related to patient outcome. However, the GCN gain and GCN status according to the 
ASCO/CAP 2013 guideline were independent prognostic factors.
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Background
Gene copy number (GCN) variation, i.e., copy number 
difference in a genomic segment, occurs commonly and 
is one of the main mechanisms in shaping the human 
genome [1]. GCN variation has been found to play an 
important role in the stimulation of cell proliferation and 
decrease of apoptosis as well as in promoting develop-
ment and progression of various cancers [1, 2]. Recent 
advancements in molecular genetics have made it pos-
sible to detect various GCN changes in human cancers 
[1, 2]. To date, many studies have reported the prognos-
tic and predictive value of GCN variation in breast, lung, 
gastric and colorectal cancer (CRC) [3, 4]. Investigation 
of the molecular profiles of malignant cells may yield 
valuable prognostic information about each type of can-
cer. In addition, the sub-classification based on genetic 
alterations is also essential to select the patients who may 
benefit from drugs specifically targeted to a particular 
molecular alteration. Despite these clinical implications, 
the appropriate and standardized criterion to define 
positivity of each GCN variation remains uncertain, par-
ticularly in CRC. Therefore, further studies are required 
to develop the adequate criterion for the identifica-
tion of genetic alterations and determination of reliable 
biomarkers.
CRC is known to be a heterogeneous disease with 
diverse molecular alterations including genetic changes 
in expression of c-MYC and MET, members of the 
human epidermal growth factor receptor (EGFR) family 
[5]. Human EGFR is a receptor kinase, which is a part of a 
complex signaling cascade that regulates cell proliferation 
and differentiation. EGFR is a representative member of 
the EGFR family. Dysregulation of EGFR expression is 
considered to be an important genetic alteration in the 
targeted treatment of advanced CRC. Several studies 
have assessed the prognostic value for overall survival 
of patients and predictive effect of the anti-EGFR treat-
ment in CRC [6, 7]. However, the results of these studies 
remain unclear. This may be explained by the relatively 
small number of patients involved and discrepant cut-off 
values of GCN variation used in these studies.
The prognostic significance of changes in HER2 
(human epidermal growth receptor 2), c-MYC and MET 
is also uncertain. Previous studies of Kavanagh et al. [8] 
and Marx et al. [9] did not consider HER2 gene amplifica-
tion as a significant prognostic factor in CRC. In afore-
mentioned studies, they used different cut-off value for 
determining the HER2 genetic status; the HER2 signal 
>4.0 [8] and the HER2/CEP17 ratio ≥2.0 [9]. However, 
there had been some controversy about the cut-off value 
and the prognostic significance of HER2 gene altera-
tions in CRC [10, 11]. In CRC, a number of studies have 
addressed the prognostic and predictive value of c-MYC 
and MET gene alterations applying different criteria, 
such as the target gene/corresponding CEP signal ratio 
of ≥2–3 for amplification and the target GCN gain of ≥4 
copies [12–15]. Only few studies have been examined 
the GCN alteration of these genes with a criterion of the 
ASCO/CAP 2013 guideline for HER2 testing of breast 
cancer.
In this study, we analysed GCN variation of the EGFR, 
HER2, c-MYC, and MET genes in 334 colorectal cancer 
tissue samples using silver-enhanced in situ hybridization 
(SISH). In particular, we defined GCN variation accord-
ing to several criteria and compared them with clinico-
pathological data and patient outcomes.
Methods
Patients and tissue samples
We examined 334 patients who underwent surgical 
resection of CRC tumours at the Seoul National Uni-
versity Bundang Hospital (Seongnam, South Korea) in 
the period between January 2005 and December 2006. 
The clinicopathological information and clinical follow-
up data were obtained from the patients’ medical and 
pathological records. The patients who underwent pre-
operative chemotherapy or radiotherapy were excluded. 
The pathologic tumor-node-metastasis (pTNM) stage 
was defined according to the 7th edition of the Ameri-
can Joint Committee on Cancer (AJCC) staging system. 
The location of CRC was defined as follows: right colon 
(including caecum, ascending colon, hepatic flexure 
and transverse colon), left colon (including splenic flex-
ure, descending colon and sigmoid colon) and rectum. 
Progression-free survival (PFS) and overall survival (OS) 
were defined as periods from the date of surgical treat-
ment until the date of disease progression and the date of 
cancer-related death, respectively.
Tissue microarray (TMA)
TMA was constructed using tissue samples with a 2-mm 
core diameter. The representative core areas of CRC 
specimens were obtained from the paraffin-embedded 
formalin-fixed tissue blocks and transferred into new 
TMA blocks, as previously described [16].
Dual‑colour silver‑enhanced in situ hybridization
The genetic status of EGFR, HER2, c-MYC, and MET was 
evaluated by the dual-colour SISH technique. Briefly, 
consecutive unstained TMA slides were stained following 
the manufacturer’s protocol using the target gene DNA 
and corresponding CEP probes. The following probes 
were used: EGFR DNA and Chromosome 7 probes, 
HER2 DNA and Chromosome 17 probes, c-MYC DNA 
and Chromosome 8 probes, and MET DNA and Chro-
mosome 7 probes (Ventana Medical System, Tucson, 
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AZ, USA). The target gene DNA and CEP probes were 
allowed to co-hybridize on the same slides and were visu-
alized by the Ventana ultraView SISH detection kit on the 
Ventana BenchMark XT automated slide stainer. The tar-
get gene and corresponding CEP signals were detected as 
black and red signals, respectively.
Evaluation of gene copy number variation
We interpreted the SISH signals in the hot spots of the 
target gene and corresponding CEP signals under 20× or 
40× objectives. We counted the signals in each core on 
60, 20, 50, and 100 overlapping tumour cell nuclei for the 
EGFR, HER2 c-MYC and MET genes, respectively. When 
there were clusters with many overlapping SISH signals, 
we counted the small clusters as six signals and large 
clusters—as twelve signals.
In the present study, the copy number status of the four 
genes was assessed by three different methods. Gene 
amplification was defined as the target gene per CEP 
signal ratio of ≥2.0 in counted tumour cell nuclei. To 
define gene copy number gain, we used a cut-off value of 
the average gene copy number being equal to or greater 
than 4. The gene copy number variation was also ana-
lysed according to the 2013 American Society of Clini-
cal Oncology/College of American Pathologists (ASCO/
CAP) HER2 testing criterion of breast cancer [17]. The 
result was considered to be positive if the target gene/
CEP ratio was ≥2.0 or if the average gene copy number 
was ≥6.0 signals. The value of the target gene/CEP ratio 
<2.0 with an average gene copy number ≥4.0 and <6.0 
signals was regarded as an equivocal result.
Microsatellite instability (MSI) analysis
MSI analysis was carried out for each patient using a 
representative tumour region and corresponding nor-
mal regions. To evaluate the MSI status of CRC, a panel 
of five microsatellite markers including BAT-26, BAT-25, 
D5S346, D17S250, and S2S123 were analysed using auto-
nomic sequencing according to the previously described 
protocol [12].
Genomic data from the cancer genome atlas (TCGA)
We used the publicly available and downloaded genetic 
data set of aforementioned four genes from TCGA portal 
(http://cbioportal.org). The putative copy number altera-
tion data was derived from Genome-Wide Human SNP 
Array 6.0 and analysed by the GISTIC 2.0 algorithm. The 
copy number alteration status was classified into five 
group; homozygous deletion, heterozygous deletion, neu-
tral, gain, and high level amplification. Clinicopathologic 
parameters including MSI status were also obtained.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware package, version 21.0 (IBM Corp., Armonk, NY, 
USA). The Chi square and Fisher’s exact tests were used 
to evaluate the association between the gene status and 
clinicopathological characteristics. The Kaplan–Meier 
analysis with the log-rank test was performed to deter-
mine the prognostic significance for overall survival, and 
multivariate Cox proportional hazard regression analysis 
was used to identify the independent prognostic factors. 




The patient group consisted of 185 men (55.4%) and 149 
women (44.6%) with the mean age of 64.04 ± 11.57 years 
(range 20–95). CRC tumours located in the right colon, 
left colon, and rectum accounted for 93 (27.8%), 127 
(38.0%) and 114 (34.1%) individual cases, respectively. 
Of these cases, 303 (90.7%) were low grade tumours and 
31 (9.3%) cases were high grade tumours. The pTNM 
stage of resected specimens was classified according to 
the AJCC 7th edition. The distribution of pTNM stages 
was as follows: stage I—36 (10.8%); stage II—109 (32.6%); 
stage III—128 (38.3%); and stage IV—61 (18.3%). The 
results of the MSI analysis were available in 323 cases of 
which 296 (91.6%) cases were categorized as Microsatel-
lite Stable/MSI-Low and 27 (8.4%) cases were categorized 
as MSI-High. Table 1 shows detailed clinicopathological 
characteristics of the CRC cases studied.
Genetic status according to different criteria
Among the 334 CRC cases, amplification of EGFR, HER2, 
c-MYC, and MET was observed in 8 (2.4%), 20 (6.0%), 29 
(8.7%) and 14 (4.2%) cases, respectively. Amplification 
of these genes occurred in a mutually exclusive man-
ner except for five cases, where co-amplification of two 
genes was observed. These five cases harboured HER2/
MET co-amplification (two cases, 0.6%), HER2/c-MYC 
co-amplification (two cases, 0.6%), and EGFR/c-MYC 
co-amplification (one case, 0.3%). Application of a GCN 
gain cut-off revealed that 109 cases (32.6%) harboured 
GCN gain in  ≥1 gene. Among these 109 cases, 32.1% 
(35/109) had multiple GCN gains in ≥2 genes. When the 
ASCO/CAP guideline was applied, 116 cases (34.7%) had 
positive or equivocal results. Furthermore, there were 
35 cases (30.2%) of patients with equivocal or positive 
results in two and more genes. The detailed information 
on the genetic status of each of the four genes studied is 
described in Fig. 1.
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Association between the clinicopathological factors 
and genetic status
Next, we assessed the association between clinicopatho-
logical factors and genetic status of each of the four 
studied genes. EGFR amplification and GCN gain were 
not significantly associated with the tumour location, 
pathological stage, or MSI status (all P  >  0.05). Using 
the ASCO/CAP criterion, EGFR positivity was signifi-
cantly related to the pathological stage (P =  0.045). For 
the HER2 gene, there was a trend towards association of 
HER2 gene expression alterations with the tumour loca-
tion in the rectum if any of the three criteria was used 
(P = 0.011, P = 0.073, and P = 0.010 for the amplifica-
tion status, GCN gain and ASCO/CAP criterion, respec-
tively). An association was also observed between c-MYC 
GCN gain and tumour location (P =  0.056, P =  0.042 
and P = 0.083 for the amplification status, GCN gain and 
ASCO/CAP criterion, respectively). At the same time, 
HER2 and c-MYC alterations were not related to the 
pathological stage or MSI status (all P  >  0.05). In addi-
tion, MET GCN gain and positivity according to the 
ASCO/CAP criterion showed an association with the 
pathological stage (P  =  0.003 and P  =  0.020, respec-
tively). The genetic alterations in EGFR, HER2, c-MYC, 
and MET assessed by three different criteria were almost 
mutually exclusive with the MSI-H status, as expected 
(Table 2) but the effects did not reach statistical signifi-
cance (all P > 0.05).
Patient outcome according to the genetic status of EGFR, 
HER2, c‑MYC and MET
To determine and compare the prognostic significance 
of EGFR, HER2, c-MYC, and MET alterations accord-
ing to the three criteria defined above, survival analy-
sis was performed using follow-up data collected for 
all patients. The median follow-up period comprised 
66.1 months (range 0.6–85.1 months). As shown in Fig. 2, 
CRC patients with c-MYC and MET GCN gains, deter-
mined after the application of the GCN gain cut-off value 
as defined above, showed shorter OS compared to the 
patient group without these genetic changes (P =  0.017 
and P = 0.010, respectively). The EGFR GCN gain tended 
to be associated with poor prognosis but the effect did 
not reach statistical significance (P =  0.070). When we 
applied the ASCO/CAP criterion, we observed statisti-
cally significant effects of the EGFR and c-MYC altera-
tions on OS. The prognosis for the EGFR positive or 
equivocal CRC group was worse than for the patients 
from the EGFR negative CRC group (P < 0.001). Patients 
with a positive c-MYC result also had significantly shorter 
OS (P = 0.044). Interestingly, when the ASCO/CAP test-
ing criterion was applied, patients with equivocal results 
for these genes tended to have the worst prognosis in our 
cohort (Fig. 2).
Cumulative analysis of the effect of EGFR, HER2, c‑MYC 
and MET alterations on overall survival
We also performed the cumulative analysis of EGFR, 
HER2, c-MYC and MET status defined by these three 
criteria. CRC patients with amplification of any of these 
genes were found in 19.8% (66/334) of cases. GCN gain 
was observed in 32.6% (109/334). Equivocal or posi-
tive results according to the ASCO/CAP guideline 
were detected in 34.7% (116/334) cases (Table  3). In 
the Kaplan–Meier survival analysis, CRC cases with 
Table 1 Clinicopathologic features of 334 CRC patients
SD standard deviation, MSI microsatellite instability, MSS microsatellite instability 
stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
Characteristic Examined no. (%)
Age (years)
 Mean ± SD 64.04 ± 11.57
 Range 20–95
Tumor size (cm)
 Mean ± SD 5.32 ± 2.21
 Range 1.0–13.0
Sex
 Male 185 (55.4)
 Female 149 (44.6)
Location
 Right 93 (27.8)
 Left 127 (38.0)
 Rectum 114 (34.1)
Histologic grade
 Low grade 303 (90.7)
 High grade 31 (9.3)
Tumor border
 Expanding 49 (14.7%)
 Infiltrative 285 (85.3%)
Lymphatic invasion
 Absent 143 (42.8%)
 Present 191 (57.2%)
Venous invasion
 Absent 272 (81.4%)
 Present 62 (18.6%)
Neural invasion
 Absent 231 (69.2%)
 Present 103 (30.8%)
pTNM stage
 I–III 273 (81.7)
 IV 61 (18.3)
MSI status (n = 323)
 MSS/MSI‑L 296 (91.6)
 MSI‑H 27 (8.4)
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Fig. 1 Distribution of EGFR, HER2, c‑MYC, and MET genetic alterations according to (a) amplification data, (b) GCN gain results and (c) ASCO/CAP 
criterion
Page 6 of 12Kwak et al. J Transl Med  (2017) 15:167 
Table 2 Correlation of genetic alteration according to the various criteria
MSI microsatellite instability, MSS microsatellite instability stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, GCN gene copy number, CN 
copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists
Characteristics Amplification GCN gain ASCO/CAP criteria
Negative Positive P CN <4 4≤ CN P Negative Equivocal Positive P
EGFR
 Location 1.000 0.803 0.419
  Right colon 91 (97.8%) 2 (2.2%) 89 (95.7%) 4 (4.3%) 89 (95.7%) 2 (2.2%) 2 (2.2%)
  Left colon 124 (97.6%) 3 (2.4%) 123 (96.9%) 4 (3.1%) 123 (96.9%) 0 (0%) 4 (3.1%)
  Rectum 111 (97.4%) 3 (2.6%) 111 (97.4%) 3 (2.6%) 111 (97.4%) 0 (0%) 3 (2.6%)
 pTNM stage 1.000 0.429 0.045
  I–III 266 (97.4%) 7 (2.6%) 265 (97.1%) 8 (2.9%) 265 (97.1%) 0 (0%) 8 (2.9%)
  IV 60 (98.4%) 1 (1.6%) 58 (95.1%) 3 (4.9%) 58 (95.1%) 2 (3.3%) 1 (1.6%)
 MSI status (n = 323) 1.000 0.609 1.000
  MSS/MSI‑L 288 (97.3%) 8 (2.7%) 285 (96.3%) 11 (3.7%) 285 (96.3%) 2 (0.7%) 9 (3.0%)
  MSI‑H 27 (100%) 0 (0%) 27 (100%) 0 (0%) 27 (100%) 0 (0%) 0 (0%)
HER2
 Location 0.011 0.073 0.015
  Right colon 90 (96.8%) 3 (3.2%) 89 (95.7%) 4 (4.3%) 89 (95.7%) 1 (1.1%) 3 (3.2%)
  Left colon 123 (96.9%) 4 (3.1%) 117 (92.1%) 10 (7.9%) 116 (91.3%) 7 (5.5%) 4 (3.1%)
  Rectum 101 (88.6%) 13 (11.4%) 99 (86.8%) 15 (13.2%) 99 (86.8%) 2 (1.8%) 13 (11.4%)
 pTNM stage 1.000 0.248 0.422
  I–III 256 (93.8%) 17 (6.2%) 247 (90.5%) 26 (9.5%) 246 (90.1%) 10 (3.7%) 17 (6.2%)
  IV 58 (95.1%) 3 (4.9%) 58 (95.1%) 3 (4.9%) 58 (95.1%) 0 (0%) 3 (4.9%)
MSI status (n = 323) 1.000 0.491 1.000
 MSS/MSI‑L 278 (93.9%) 18 (6.1%) 269 (90.9%) 27 (9.1%) 268 (90.5%) 10 (3.4%) 18 (6.1%)
  MSI‑H 26 (96.3%) 1 (3.7%) 26 (96.3%) 1 (3.7%) 26 (96.3%) 0 (0%) 1 (3.7%)
c‑MYC
 Location 0.056 0.042 0.083
  Right colon 88 (94.6%) 5 (5.4%) 82 (88.2%) 11 (11.8%) 82 (88.2%) 6 (6.5%) 5 (5.4%)
  Left colon 110 (86.6%) 17 (13.4%) 96 (75.6%) 31 (24.4%) 96 (75.6%) 13 (10.2%) 18 (14.2%)
  Rectum 107 (93.9%) 7 (6.1%) 96 (84.2%) 18 (15.8%) 96 (84.2%) 11 (9.6%) 7 (6.1%)
 pTNM stage 0.723 0.136 0.199
  I–III 250 (91.6%) 23 (8.4%) 228 (83.5%) 45 (16.5%) 228 (83.5%) 21 (7.7%) 24 (8.8%)
  IV 55 (90.2%) 6 (9.8%) 46 (75.4%) 15 (24.6%) 46 (75.4%) 9 (14.8%) 6 (9.8%)
 MSI status (n = 323) 0.491 0.061 0.155
  MSS/MSI‑L 269 (90.9%) 27 (9.1%) 240 (81.1%) 56 (18.9%) 240 (81.1%) 28 (9.5%) 28 (9.5%)
  MSI‑H 26 (96.3%) 1 (3.7%) 26 (96.3%) 1 (3.7%) 26 (96.3%) 0 (0%) 1 (3.7%)
MET
 Location 0.427 0.602 0.536
  Right colon 87 (93.5%) 6 (6.5%) 77 (82.8%) 16 (17.2%) 75 (80.6%) 10 (10.8%) 8 (8.6%)
  Left colon 122 (96.1%) 5 (3.9%) 109 (85.8%) 18 (14.2%) 106 (83.5%) 15 (11.8%) 6 (4.7%)
  Rectum 111 (97.4%) 3 (2.6%) 100 (87.7% 14 (12.3%) 99 (86.8%) 11 (9.6%) 4 (3.5%)
 pTNM stage 1.000 0.003 0.020
  I–III 261 (95.6%) 12 (4.4%) 241 (88.3%) 32 (11.7%) 235 (86.1%) 23 (8.4%) 15 (5.5%)
  IV 59 (96.7%) 2 (3.3%) 45 (73.8%) 16 (26.2%) 45 (73.8%) 13 (21.3%) 3 (4.9%)
 MSI status (n = 323) 0.609 0.147 0.298
  MSS/MSI‑L 284 (95.9%) 12 (4.1%) 252 (85.1%) 44 (14.9%) 247 (83.4%) 33 (11.1%) 16 (5.4%)
  MSI‑H 27 (100%) 0 (0%) 26 (96.3%) 1 (3.7%) 26 (96.3%) 1 (3.7%) 0 (0%)
Page 7 of 12Kwak et al. J Transl Med  (2017) 15:167 
Fig. 2 Kaplan–Meier survival analysis of overall survival of CRC patients with EGFR, HER2, c‑MYC, and MET GCN changes, which were defined accord‑
ing to the following criteria: a, d, g, j amplification; b, e, h, k GCN gain and c, f, i, l ASCO/CAP criterion
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GCN gain was significantly associated with poor OS 
(P = 0.006). Also, the patients with equivocal or positive 
results defined by the ASCO/CAP criterion in any of the 
four genes were had worse outcome (P =  0.022). How-
ever, amplification of any of these genes was not associ-
ated with OS (P =  0.394) (Fig.  3). Multivariate analysis 
proved that genetic alterations of EGFR, HER2, c-MYC, 
or MET defined by the GCN gain or the ASCO/CAP cri-
terion were significant unfavourable prognostic factors 
of OS (HR, 1.750 95% CI, 1.145–2.673; P =  0.010 and 
HR, 1.676 95% CI, 1.097–2.561; P = 0.017, respectively) 
(Table 4).
Analysis of TCGA data
A total of 257 cases of CRC were used for comparative 
analysis. High-level amplification of EGFR, HER2, c-
MYC, and MET was observed in 1 (0.4%), 8 (3.1%), 11 
(4.3%) and 1 (0.4%) cases, respectively (Fig.  4). There 
was no case had co-amplification in TCGA cohort. The 
amplification rate of each gene was slightly lower than 
the rate showed in 334 Korean CRC cohort. Copy num-
ber gain of EGFR, HER2, c-MYC, and MET was observed 
in 114 (44.4%), 40 (15.6%), 119 (46.3%) and 103 (40.1%) 
cases, respectively. Of 257 cases, 128 (49.8%) harboured 
GCN gain in ≥1 gene.
We analyzed the association between clinicopatho-
logical factors and genetic status of the four genes using 
TCGA data in like manner used for Korean CRC cohort. 
Similar to the results of Korean CRC cohort, there was 
no statistical significance between the status of high-level 
amplification in ≥1 gene and MSI status (P = 0.326). The 
status of GCN gain in ≥1 gene was significantly corre-
lated with MSI-H status (P < 0.001). Other clinicopatho-
logical parameters including pathologic stage had no 
significant correlation with gene copy number status of 
four genes (data not shown).
None of the copy number alteration status of each four 
genes had association with OS. In cumulative analysis, 
there was no significant difference of OS between the 
patients with high-level amplification of any of four genes 
Table 3 Combined clinicopathologic analysis according to the various criteria
MSI microsatellite instability, MSS microsatellite instability stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, GCN gene copy number, CN 
copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists
Characteristics Amplification GCN gain 2013 ASCO/CAP guideline
Negative Positive P CN< 4 4 ≤CN P Negative Equivocal or positive P
Location 0.403 0.241 0.213
 Right colon 79 (84.9%) 14 (15.1%) 69 (74.2%) 24 (25.8%) 67 (72.0%) 26 (28.0%)
 Left colon 100 (78.7%) 27 (21.3%) 81 (63.8%) 46 (36.2%) 77 (60.6%) 50 (39.4%)
 Rectum 89 (78.1%) 25 (21.9%) 75 (65.8%) 39 (34.2%) 74 (64.9%) 40 (35.1%)
pTNM stage 0.708 0.124 0.257
 I–III 218 (79.9%) 55 (20.1%) 189 (69.2%) 84 (30.8%) 182 (66.7%) 91 (33.3%)
 IV 50 (82.0%) 11 (18.0%) 36 (59.0%) 25 (41.0%) 36 (59.0%) 25 (41.0%)
MSI status (n = 323) 0.097 0.004 0.002
 MSS/MSI‑L 235 (79.4%) 61 (20.6%) 194 (65.5%) 102 (34.5%) 188 (63.5%) 108 (36.5%)
 MSI‑H 25 (92.6%) 2 (7.4%) 25 (92.6%) 2 (7.4%) 25 (92.6%) 2 (7.4%)
Fig. 3 Cumulative survival analysis of overall survival of CRC patients with EGFR/HER2/c‑MYC/MET GCN alteration, which were defined according to 
the following criteria: a amplification; b GCN gain; c ASCO/CAP criterion
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or patients with no amplification (P = 0.704). The status 
of GCN gain in ≥1 gene also had no prognostic correla-
tion (P = 0.691).
Discussion
Much effort has been focused on improving CRC treat-
ment strategies, and a number of genetic alterations 
associated with CRC development have been evaluated. 
Aberrant activation of EGFR, HER2, c-MYC, or MET is 
considered to be a promising target for specific molecu-
lar treatments in various cancers, including CRC [7, 12, 
15, 18]. Although many studies suggested a prognostic 
and predictive impact of such genetic alterations, a 
standardized criterion for them in CRC has not been 
established. In this study, we evaluated the genetic status 
of EGFR, HER2, c-MYC and MET in 334 CRC samples 
and its association with patients’ prognosis in 334 CRC 
samples using dual-colour SISH analysis. We evaluated 
the applicability of the ASCO/CAP HER2 guideline crite-
rion for breast cancer to assess the EGFR, HER2, c-MYC, 
and MET gene status. We also assessed GCN gain and 
amplification of these genes in the CRC samples. We 
found that comparative analysis of the genetic status by 
using several criteria supported the conclusion that GCN 
Table 4 Univariate and multivariate analysis according to the various criteria
MSI microsatellite instability, GCN gene copy number, ASCO/CAP American Society of Clinical Oncology/College of American Pathologists
Factors Univariate analysis P
Age 1.022 (1.033–1.042) 0.021
Sex 0.823 (0.545–1.245) 0.357
Tumor size 1.150 (1.058–1.251) 0.001
Histologic grade (high vs. low) 3.582 (2.136–6.007) <0.001
Tumor border (infiltrative vs. expanding) 4.173 (1.532–11.365) 0.005
Lymphatic invasion (present vs. absent) 3.345 (2.039–5.488) <0.001
Venous invasion (present vs. absent) 3.777 (2.484–5.741) <0.001
Neural invasion (present vs. absent) 3.601 (2.389–5.427) <0.001
pTNM stage (IV vs. I–III) 7.727 (5.109–11.687) <0.001
Amplification in any gene (≥2 vs. <2) 1.235 (0.759–2.008) 0.395
GCN gain in any gene (≥4 vs. <4) 1.770 (1.175–2.666) 0.006
ASCO/CAP criteria in any gene (positive/equivocal vs. negative) 1.608 (1.067–2.421) 0.023
Factors Multivariate analysis P
GCN gain
 Age 1.038 (1.015–1.061) 0.001
 Sex 0.643 (0.414–0.999) 0.049
 Tumor size 1.115 (1.001–1.243) 0.048
 Histologic grade (high vs. low) 2.843 (1.571–5.143) 0.001
 Tumor border (infiltrative vs. expanding) 2.550 (0.899–7.231) 0.078
 Lymphatic invasion (present vs. absent) 1.296 (0.737–2.276) 0.368
 Venous invasion (present vs. absent) 1.197 (0.720–1.989) 0.489
 Neural invasion (present vs. absent) 2.400 (1.506–3.827) <0.001
 pTNM stage (IV vs. I–III) 4.791 (2.891–7.940) <0.001
 GCN gain in any gene (≥4 vs. <4) 1.750 (1.145–2.673) 0.010
ASCO/CAP criteria
 Age 1.038 (1.016–1.061) 0.001
 Sex 0.645 (0.415–1.003) 0.052
 Tumor size 1.114 (0.999–1.241) 0.052
 Histologic grade (high vs. low) 2.857 (1.578–5.174) 0.001
 Tumor border (infiltrative vs. expanding) 2.525 (0.891–7.155) 0.081
 Lymphatic invasion (present vs. absent) 1.289 (0.734–2.265) 0.377
 Venous invasion (present vs. absent) 1.197 (0.721–1.987) 0.488
 Neural invasion (present vs. absent) 2.414 (1.514–3.850) <0.001
 pTNM stage (IV vs. I–III) 4.868 (2.941–8.057) <0.001
 ASCO/CAP criteria in any gene (positive/equivocal vs. negative) 1.676 (1.097–2.561) 0.017
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gain and GCN result according to the ASCO/CAP crite-
ria were independent prognostic factors in consecutive 
CRC patients.
Genetic alterations of HER2 have been studied particu-
larly actively in breast and gastric cancers [17, 19]. Cur-
rently, evaluation of the HER2 status in breast cancer is 
included as part of a routine test according to the ASCO/
CAP criteria. However, because many previous studies 
evaluated the genomic status of these genes in CRC by 
disparate criteria, the prognostic and predictive impact of 
the HER2 status has been controversial. Our study is one 
of the few studies, in which genetic changes in CRC were 
assessed according to the 2013 ASCO/CAP criterion. 
When we applied the ASCO/CAP HER2 test criterion to 
CRC cases, EGFR and c-MYC positivity showed signifi-
cant association with poor prognosis. In the cumulative 
analysis of EGFR, HER2, c-MYC, and MET, CRC cases 
with positive results for any of these genes was a signifi-
cant predictor of poor overall survival. Although further 
studies that would evaluate this concordance with fluo-
rescence in situ hybridization and immunohistochemistry 
methods are needed, our findings suggest that the 2013 
ASCO/CAP HER2 testing criterion for breast cancer is 
applicable for determination of genetic changes in CRC.
We defined GCN gain as the signal equal or higher than 
the cut-off value of 4.0 for each gene signal per cell. In our 
results, GCN gain in the EGFR, c-MYC, and MET genes, 
determined according to this criterion, was significantly 
associated with patient survival. In the multivariate anal-
ysis, application of this cut-off value revealed that GCN 
gain in any of the four genes analysed was a significant 
poor prognosis factor in CRC, in line with the results 
obtained using the ASCO/CAP criterion. In addition, we 
defined the equivocal result according to the ASCO/CAP 
guideline, namely when 6> gene copy number ≥4.0 and 
found that for such CRC cases, the prognosis was worse 
than for those with negative or positive results. Thus, we 
demonstrated in our study that the cut-off value of ≥4.0 
as well as the ASCO/CAP criterion could be applied as a 
reliable cut-off point to determine GCN gain as a molec-
ular prognostic marker in CRC.
As has been published previously [6, 13, 14], we observed 
that the rates of c-MYC and MET amplification were rela-
tively low. Interestingly, approximately 20–30% of genetic 
alterations in c-MYC and MET were detected using 
GCN gain and the ASCO/CAP criteria. The discrep-
ancy was also found in the rates of CRC cases with multi-
ple genetic changes. There were only 5 cases of CRC with 
Fig. 4 Comparison of the rate of GCN alteration obtained by in situ hybridization methods and array‑based platform: a EGFR, b HER2, c c‑MYC, and 
d MET
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amplifications of multiple genes. However, there were 35 
cases of CRC accompanied by GCN gains and ASCO/
CAP positivity in multiple genes. These genetic changes 
were considered to have clinical significance because they 
were associated with poor prognosis. Specific drugs target-
ing EGFR represent one of the main treatment strategies in 
advanced CRC patients [20, 21], and some studies reported 
the association between the EGFR GCN and resistance to 
anti-EGFR treatment [7, 22, 23]. Currently, the association 
between other genetic changes and the resistance to EGFR 
inhibitors is a subject of intense scientific scrutiny. Further-
more, attempts to exploit these genetic changes for targeted 
therapy are currently underway in several preclinical and 
clinical trials [18, 24, 25]. Based on this knowledge, the abil-
ity to detect the presence of these genetic changes in CRC 
has a great clinical significance. Our findings, therefore, 
suggest that GCN gain and the ASCO/CAP criterion are 
more useful to detect genetic alterations accurately.
In present study, we analysed somatic gene copy altera-
tion of TCGA dataset and compare the results from that 
of Korean CRC cohort. The rate of high-level amplifica-
tion of each gene using array-based method was lower 
than amplification rate obtained by SISH method. The 
proportion of MET gene amplification was highest and 
that of EGFR gene amplification was lowest among four 
genes in both cohorts. Correlation between copy number 
gain and MSI-H status was also observed in both cohorts. 
However the direct comparison of these results derived 
by different detection methods would be unsuitable.
Several platforms for detection of GCN alteration are 
currently available, but it is still unclear whether array-
based platform is an ideal detection method. A lack of 
reproducibility and concordance for array-based method 
has been shown in previously published study by Pinto 
et  al. [26]. Normal tissue contamination or unknown 
ploidies of tumor cells is another challenges for array-
based platform. In HER2 testing for breast or gastric can-
cer, in situ hybridization method is the gold standard to 
assess patient’s further treatment [27]. In this study, the 
prognostic significance of GCN gain was only confirmed 
in Korean CRC when the genetic status analysed by GCN 
gain and ASCO/CAP guideline criterion. From the clini-
cal viewpoint, detection of GCN alteration by classic 
in situ hybridization method could be more useful.
Despite several genes being proposed as prognostic 
markers based on the GCN gain or the ASCO/CAP crite-
rion data, our results have some limitations. Some genetic 
alterations, including changes in EGFR and MET, were 
observed at relatively low frequencies, and these altera-
tions were detected in less than 5% of cancers analysed in 
our study. Based on our results, evaluation of these genetic 
changes in large cohorts of samples using GCN gain or the 
ASCO/CAP guideline criterion is needed to determine 
their prognostic impact. Additionally, EGFR, HER2, 
c-MYC, and MET have been identified to be potential 
biomarkers that predict the efficacy of the pharmacologi-
cal treatments targeted against protein products of these 
genes in various cancers. The determination and exact 
evaluation of cases with positive copy number changes in 
these genes may help in developing more effective treat-
ment strategies by selecting patients who may benefit from 
the targeted treatments directed against the corresponding 
genetic changes. Further studies are necessary to explore 
if the GCN gain defined by the cut-off point of 4.0 and by 
the ASCO/CAP criterion has a predictive impact on the 
efficacy of treatments targeted to specific genetic changes 
in CRC. We analysed the genetic status using TMA, which 
may not be representative of the whole CRC tumour due 
to the use of only small cores taken from each specimen. 
Some previous studies also reported that cancers often 
had genomic heterogeneity [7, 9], so a small tissue core of 
TMA may not fully represent each cancer at the genetic 
level. Thus, we need efficient validation of the heterogene-
ity of these genetic alterations in CRC.
Conclusions
We evaluated EGFR, HER2, c-MYC, and MET gene sta-
tus by determining the degree of amplification, GCN gain 
and the 2013 ASCO/CAP HER2 testing guideline crite-
rion for breast cancer. In the cumulative analysis of these 
genes, we revealed that genetic variation in any of four 
genes according to the GCN gain defined by the cut-off 
point of 4.0 or to the ASCO/CAP criterion was an inde-
pendent prognostic factor in CRC.
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